Results 231 to 240 of about 51,902 (295)

Tissue Resident Memory Cells: Friend or Foe?

Immunology, EarlyView.
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude, Jude E. Uzonna, Janilyn Arsenio   +2 more
wiley   +1 more source

Evaluation of immunohistochemical and gene expression of Janus kinase 1 and Janus kinase 3 in the skin of different clinical types of mycosis fungoides patients - Part 1. [PDF]

An Bras Dermatol
El-Amawy HS, Mohamed Ali BM, Shareef MM, Elgarhy L.   +3 more
europepmc   +1 more source

Multi‐omics profiling of chronic immune‐mediated skin diseases: SKINERGY protocol and strategic evaluation

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The SKINERGY study will investigate six immune‐mediated inflammatory skin diseases through a nationwide collaboration across all Dutch university medical centres. Involving 720 patients and 120 healthy volunteers, it is aimed at generating a high‐quality dataset to identify biomarkers that enable personalized treatment strategies and improved disease ...
N. G. Koster, J. M. P. A. van den Reek, E. M. G. J. de Jong, S. van Beugen, A. I. M. van Laarhoven, I. Haeck, M. de Bruin‐Weller, M. L. Schuttelaar, B. Horvath, A. Gostyński, A. Knulst, M. H. Vermeer, L. Nguyen, L. Gerbens, P. Spuls, M. A. Middelkamp‐Hup, V. Exadaktylos, T. Niemeyer‐van der Kolk, A. R. Schrader, A. M. Sluijmers, J. Versteeg, B. W. M. Arents, I. van Ee, J. L. A. G. van der Zon, M. de Leeuw, T. de Leeuw, P. van den Broek, C. Berkhof, D. Vellinga, S. Weidinger, S. Dubrac, Y. Li, M. van Steensel, M. Marchetti‐Deschmann, M. Maurer, H. van der Zee, J. Damman, D. J. Hijnen, F. Wijk, M. M. B. Seyger, H. Röckmann, D. M. W. Balak, M. B. A. van Doorn, R. Rissmann, The Next Generation ImmunoDermatology (NGID) consortium, Rob Vreeken, Eva Cuypers, Boudewijn Lelieveldt, Abdoel El Ghalbzouri, Hanna Niehues, Ellen van den Bogaard, Tom Ederveen, Els van der Pool, Nanda Olde, Debra Trampe, Ellen Stijl‐’t Hart, Lisanne Wezendonk, Johan Westerhuis, Huma Shehwana, Joerg Schreiber, Jeremy Bost, Mie Bech Lukassen, Jimmy Bakker, Juliette Simons, Fauve van den Berge, Colin Spence, Elise Beljaards, Anastasiia Myronenko, Mariona Oliver   +68 more
wiley   +1 more source

Interferon-gamma signaling pathway: Modulation of key genes in the progression of glioblastoma. [PDF]

World J Biol Chem
Oropeza-Martínez E, Palacios Serrato EG, Zamora-Salas SX, Lira-Rodríguez NA, López-Mignon SH, Martinez-Benitez MB, Tecalco-Cruz AC.   +6 more
europepmc   +1 more source

Mapping malignant T‐cell states and immune circuits in Sézary syndrome by single‐cell analysis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Peripheral blood single‐cell RNA‐seq from leukaemic CTCL defined three malignant T‐cell programmes: MTC CM, MTC Reg and MTC E/EM, each with distinct features and candidate vulnerabilities. For example, inferred immune circuits highlighted actionable IL‐10/JAK–TYK2–STAT3 signalling, KIR–MHC I inhibitory interactions and myeloid/B‐cell inflammatory and ...
Beth A. Childs, Eslam A. Elghonaimy, Praveen Ramakrishnan Geethakumari, Kiran A. Kumar, Joseph F. Merola, Heather W. Goff, Todd A. Aguilera   +6 more
wiley   +1 more source

Mastering the Use of Systemic JAK Inhibitors for Atopic Dermatitis: A Dermatologist's Practical Guide. [PDF]

Am J Clin Dermatol
Jalili A, Labbouz S, Gooderham M, Ziv M, Dodiuk-Gad RP.   +4 more
europepmc   +1 more source

Cutaneous T‐cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Systematic review (51 studies; 547 patients) indicates dupilumab may unmask/worsen CTCL (mainly MF/SS). A French Delphi consensus recommends rigorous diagnostic workup, avoiding dupilumab in confirmed CTCL, discontinuing upon diagnosis, and favouring methotrexate or phototherapy.
Florent Amatore, Madeleine Neildez, Adèle de Masson, Maxime Battistella, Marie Tauber, Saskia Ingen‐Housz‐Oro, Catherine Droitcourt, Delphine Staumont‐Sallé, Marie Beylot‐Barry   +8 more
wiley   +1 more source

Engineered Fenretinide- and Tocilizumab-Releasing Janus Nanoparticles for Site-Directed Immunochemoprevention of Squamous Cell Carcinoma of the Lung. [PDF]

Pharmaceutics
Wang D, Chang A, Shea F, He Y, Spinney R, Whitsett JD, Lahann J, Mallery SR.   +7 more
europepmc   +1 more source

Long‐term efficacy of abrocitinib in patients with moderate‐to‐severe atopic dermatitis to 2 years

Journal of the European Academy of Dermatology and Venereology, EarlyView.
JADE EXTEND is an ongoing phase 3, long‐term extension study of previous abrocitinib trials. Patients were adults and adolescents ≥12 years with moderate‐to‐severe atopic dermatitis. Long‐term abrocitinib treatment resulted in clinically meaningful outcomes and improvements in patient‐reported outcomes up to Week 112 in patients with moderate‐to‐severe
Melinda J. Gooderham, Jonathan I. Silverberg, Marjolein De Bruin‐Weller, Leon Kircik, Diamant Thaçi, Zuotao Zhao, Fernando Valenzuela, Toshifumi Nomura, Andrew Selfridge, Dorothy Fan, Daniela E. Myers, Pinaki Biswas, Saleem A. Farooqui, Melissa Watkins, Herwig Koppensteiner   +14 more
wiley   +1 more source

Diversifying the triquinazine scaffold of a Janus kinase inhibitor. [PDF]

RSC Med Chem
Mulliri K, Meier K, Feuchter JD, Javor S, Meirelles MA, Reymond JL.   +5 more
europepmc   +1 more source